ALX Oncology Achieves 92% Complete Response in Non-Hodgkin Lymphoma with Evorpacept Combination
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 07 2025
0mins
Source: Globenewswire
- Clinical Trial Success: ALX Oncology's Phase 2 trial demonstrates that the combination of evorpacept with rituximab and lenalidomide achieves a 92% complete response rate in untreated indolent non-Hodgkin lymphoma patients, significantly exceeding the historical 50% response rate for standard treatment, indicating strong anti-tumor activity.
- Patient Response: Among 24 participants, the overall response rate (ORR) of 100% and a one-year progression-free survival (PFS) rate of 91% suggest that this regimen is not only well-tolerated but also effectively prolongs patient survival, enhancing ALX Oncology's competitive position in cancer treatment.
- Research Background Support: Led by Dr. Paolo Strati from The University of Texas MD Anderson Cancer Center, this study further validates the therapeutic potential of blocking CD47 in non-Hodgkin lymphoma characterized by high CD47 expression, potentially laying the groundwork for future immuno-oncology advancements.
- Future Outlook: With ongoing evaluations of minimal residual disease (MRD) eradication rates, ALX Oncology plans to advance evorpacept across multiple cancer indications, showcasing its broad application prospects in oncology treatment.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ALXO
Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.370
Low
2.00
Averages
3.00
High
4.00
Current: 1.370
Low
2.00
Averages
3.00
High
4.00
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALX Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
- Conference Participation: ALX Oncology will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its latest advancements in cancer treatment, which is expected to attract investor and industry attention.
- Leadership Introduction: CEO Jason Lettmann and CMO Barbara Klencke will jointly attend to share the company's strategic developments in novel therapy, aiming to enhance market confidence and attract potential investments.
- Live Webcast: The presentation will be live-streamed via the Investors section of ALX Oncology's website, providing convenient access to a broader audience to stay updated on the company's latest developments.
- Therapeutic Progress: ALX Oncology's lead candidate, evorpacept, is currently being evaluated in multiple clinical trials, demonstrating potential in immuno-oncology, which may lay the foundation for future cancer therapies.
Continue Reading
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
Continue Reading